menu
    • menu
    [{"orgOrder":0,"company":"Xequel Bio","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Inexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xequel Bio \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ US Department of Defense"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Agreement","leadProduct":"iNexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xequel Bio \/ Societal CDMO","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Societal CDMO"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"iNexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xequel Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Undisclosed"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Granexin","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xequel Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xequel Bio \/ Undisclosed"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Medical University of South Carolina | Spartanburg Regional Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Granexin","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xequel Bio \/ Medical University of South Carolina | Spartanburg Regional Healthcare System","highestDevelopmentStatusID":"10","companyTruncated":"Xequel Bio \/ Medical University of South Carolina | Spartanburg Regional Healthcare System"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FSR Peptide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xequel Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Undisclosed"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Spartanburg Regional Healthcare System | Medical University of South Carolina","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Zifogaptide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xequel Bio \/ Spartanburg Regional Healthcare System | Medical University of South Carolina","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Spartanburg Regional Healthcare System | Medical University of South Carolina"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zifogaptide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xequel Bio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Xequel Bio \/ Undisclosed"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zifogaptide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xequel Bio \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Xequel Bio \/ US Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by Xequel Bio

    Menu

    Xequel Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iNexin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexi...

                            Details : Under the agreement, Societal CDMO will provide to support the ongoing clinical development of iNexin™, a patented new chemical entity based on company's aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.

                            Product Name : iNexin

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            May 08, 2023

                            Lead Product(s) : iNexin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iNexin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of ...

                            Details : In clinical and preclinical studies, iNexin demonstrated acceleration of corneal healing and restoration of the ocular surface. This study demonstrated that iNexin was safe and well-tolerated and early efficacy signals were observed at the doses tested.

                            Product Name : iNexin

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            September 27, 2022

                            Lead Product(s) : iNexin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inexin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety, Tolerability and Efficacy of iNexinâ„¢ for the Treatment of the Signs and Sympto...

                            Details : Inexin is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            September 02, 2021

                            Lead Product(s) : Inexin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zifogaptide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing

                            Details : Granexin (Zifogaptide) is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Burns.

                            Product Name : Granexin

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 24, 2020

                            Lead Product(s) : Zifogaptide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FSR Peptide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

                            Details : FSR Peptide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Wound Healing.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 16, 2020

                            Lead Product(s) : FSR Peptide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zifogaptide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor ...

                            Details : Granexin (Zifogaptide) is a Peptide drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Cicatrix.

                            Product Name : granexin

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 02, 2020

                            Lead Product(s) : Zifogaptide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Granexin

                            Therapeutic Area : Podiatry

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

                            Details : Granexin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 28, 2016

                            Lead Product(s) : Granexin

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Granexin

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Medical University of South Carolina | Spartanburg Regional Healthcare System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot U...

                            Details : Granexin is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 12, 2016

                            Lead Product(s) : Granexin

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Medical University of South Carolina | Spartanburg Regional Healthcare System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Xequel Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zifogaptide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Spartanburg Regional Healthcare System | Medical University of South Carolina

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulce...

                            Details : Granexin (Zifogaptide) is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leg Ulcer.

                            Product Name : Granexin

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 12, 2016

                            Lead Product(s) : Zifogaptide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Spartanburg Regional Healthcare System | Medical University of South Carolina

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth